The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Venetoclax enhances T-cell fitness and CAR T-cell manufacturing potential in CLL
Joseph Melenhorst, PhD, Cleveland Clinic, Cleveland, OH, discusses how venetoclax-based debulking strategies improve T-cell fitness in patients with chronic lymphocytic leukemia (CLL). He explains that reducing tumor burden before cell collection leads to higher-quality T-cells for CAR T-cell manufacturing and may enhance therapeutic efficacy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
